Alliance Global Partners Comments on Cresco Labs Q4 Earnings

Cresco Labs Inc. (OTCMKTS:CRLBF) – Equities researchers at Alliance Global Partners issued their Q4 2024 EPS estimates for Cresco Labs in a research note issued to investors on Wednesday, October 30th. Alliance Global Partners analyst A. Grey forecasts that the company will earn ($0.01) per share for the quarter. The consensus estimate for Cresco Labs’ current full-year earnings is ($0.15) per share.

Several other analysts also recently commented on the stock. Roth Capital raised shares of Cresco Labs from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cresco Labs in a research note on Monday, August 12th. Finally, Ventum Cap Mkts upgraded shares of Cresco Labs to a “strong-buy” rating in a report on Friday, August 9th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $2.50.

Cresco Labs Trading Up 3.8 %

Shares of OTCMKTS CRLBF opened at $1.52 on Friday. The stock has a market cap of $739.53 million, a price-to-earnings ratio of -2.97 and a beta of 1.88. The business has a 50 day simple moving average of $1.62 and a 200 day simple moving average of $1.74. The company has a debt-to-equity ratio of 1.76, a quick ratio of 1.30 and a current ratio of 2.00. Cresco Labs has a 52 week low of $1.11 and a 52 week high of $2.65.

Cresco Labs (OTCMKTS:CRLBF) last issued its earnings results on Thursday, August 8th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.15). The firm had revenue of $184.36 million during the quarter, compared to analyst estimates of $184.26 million. Cresco Labs had a negative return on equity of 17.03% and a negative net margin of 23.07%.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.